Switching to a Biosimilar: Effie’s Experience

At the start of 2020 the government announced that coverage was changing for people who take Remicade® (infliximab) for the treatment of Crohn’s disease or ulcerative colitis.  This meant that patients receiving the biologic drug infliximab, marketed as Remicade®, would see this coverage discontinue with new coverage for the biosimilar version: Inflectra and Renflexis. 

Ulcerative colitis advocate Effie was one of those people. In this self-produced video, Effie talks all about her experiences with switching to a biosimilar, takes us through her first Inflectra infusion, and answers some of the same questions you may be asking yourself if you will be going through the same process: 

• What is a biosimilar?
• Why does she have to switch?
• Why is there a huge pushback on switching and why is she ok with it? 

For more information on biosimilars, click here.

Have you already been switched/transitioned to a biosimilar version of Remicade® (infliximab)? Take our Patient Survey